General Information of Drug (ID: DM1SV8I)

Drug Name
PHN-131 Drug Info
Synonyms
NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Phase 2/3 [1]
Cross-matching ID
PubChem CID
5360733
ChEBI ID
CHEBI:7455
CAS Number
CAS 23277-43-2
TTD Drug ID
DM1SV8I
ACDINA Drug ID
D01268

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nalbuphine DMOSQGU Pain MG30-MG3Z Approved [3]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [4]
CHLOROXINE DMFZBMQ Erythema ME64.0 Approved [5]
Difelikefalin DMHZBEO Pruritus EC90 Approved [6]
Dezocine DMJDB0Y Pain MG30-MG3Z Approved [7]
Asimadoline DMND3AB Diarrhea-predominant irritable bowel syndrome DD91.01 Phase 3 [8]
JNJ 67953964 DMJ8Y5N Major depressive disorder 6A70.3 Phase 3 [9]
CR-845 DMJYTUQ Pain MG30-MG3Z Phase 2/3 [10]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [11]
Apadoline DM1B8IT Pain MG30-MG3Z Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029095)
2 Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
5 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
8 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
9 Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
10 Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
11 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
12 Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68.